MEDVi vs Peptide Sciences
A detailed head-to-head comparison of MEDVi and Peptide Sciences — pricing, peptides, consultation models, and patient reviews.
At a Glance
RatingNo reviews
Starting Price$50/mo
Peptides2
ConsultationHybrid
Lab TestingNo
Shipping3-5 business days
Pros
- Video consultations with board-certified physicians
- Brand-name GLP-1 medications and orforglipron ($149/mo oral option) available
- Metabolic health coaching included at no extra cost
- Follow-up visits every 4-6 weeks
- Broad state coverage (47 states)
- Insurance accepted for brand-name medications
Cons
- Compounded GLP-1 options permanently unavailable
- Lab work not included in the program
- Founded in 2022 with a limited public track record compared to established competitors
- Physicians are not specifically obesity medicine specialists
- The "concierge" branding may set expectations higher than the actual level of personalization
- Not available in all 50 states
RatingNo reviews
Starting PriceN/A
Peptides0
ConsultationAsync Telehealth
Lab TestingNo
Shipping2-5 business days
Pros
- Research-grade peptide purity
- Full spectrum peptide availability
- Third-party purity testing
- Fast shipping (2-5 days)
- Established research supplier
- Competitive research pricing
Cons
- Research use only - not for human consumption
- No medical supervision or guidance
- No prescription or consultation services
- Legal gray area for personal use
- Quality control varies by batch
Pros & Cons
Peptide Pricing Comparison
| Peptide | MEDVi | Peptide Sciences |
|---|---|---|
| Semaglutide | $50/monthly $149/monthly | Not offered |
| Tirzepatide | Price unavailable | Not offered |
Frequently Asked Questions
Is MEDVi or Peptide Sciences better?
MEDVi offers 2 peptides and hybrid consultations. Peptide Sciences offers 0 peptides and async telehealth consultations. The best choice depends on which peptides you need, your budget, and preferred consultation model.
Which is cheaper, MEDVi or Peptide Sciences?
See the pricing table above for a detailed comparison.